Although the amivantamab–lazertinib combination demonstrates clinical benefits for EGFR-mutated advanced NSCLC, its substantial treatment costs pose significant challenges to patient accessibility and healthcare economic sustainability. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.